{
  "success": true,
  "pagesUsed": [
    1,
    10
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "CLINICAL TRIAL PROTOCOL SYNOPSIS",
        "text": "CLINICAL TRIAL PROTOCOL SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "CLINICAL TRIAL PROTOCOL SYNOPSIS",
        "sectionType": {
          "id": "1362215f-8744-4698-86e5-c4590834694e",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "82059818-dc40-4c81-b6df-4aee22897889",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5"
        ]
      },
      {
        "id": "nc_3",
        "name": "RATIONALE, OBJECTIVES, AND BENEFIT-RISK ASSESSMENT",
        "text": "RATIONALE, OBJECTIVES, AND BENEFIT-RISK ASSESSMENT",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "RATIONALE, OBJECTIVES, AND BENEFIT-RISK ASSESSMENT",
        "sectionType": {
          "id": "97952a9a-720d-44fc-925b-76a7079cc34e",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2",
          "nci_3_3"
        ]
      },
      {
        "id": "nc_4",
        "name": "DESCRIPTION OF DESIGN AND TRIAL POPULATION",
        "text": "DESCRIPTION OF DESIGN AND TRIAL POPULATION",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "DESCRIPTION OF DESIGN AND TRIAL POPULATION",
        "sectionType": {
          "id": "fa5f1f2c-ff00-41c4-a34e-5f8f7adb8efc",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9",
          "nci_4_10",
          "nci_4_11",
          "nci_4_12",
          "nci_4_13"
        ]
      },
      {
        "id": "nc_5",
        "name": "TREATMENTS",
        "text": "TREATMENTS",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "TREATMENTS",
        "sectionType": {
          "id": "40baa622-1eca-4835-87f3-a4149c263fa6",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3",
          "nci_5_4",
          "nci_5_5",
          "nci_5_6",
          "nci_5_7",
          "nci_5_8",
          "nci_5_9",
          "nci_5_10"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_2_1",
        "name": "MEDICAL BACKGROUND",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "MEDICAL BACKGROUND"
      },
      {
        "id": "nci_2_2",
        "name": "DRUG PROFILE",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "DRUG PROFILE"
      },
      {
        "id": "nci_2_3",
        "name": "Non-clinical assessment of safety",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.1",
        "sectionTitle": "Non-clinical assessment of safety"
      },
      {
        "id": "nci_2_4",
        "name": "Clinical pharmacokinetics",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2",
        "sectionTitle": "Clinical pharmacokinetics"
      },
      {
        "id": "nci_2_5",
        "name": "Clinical efficacy and safety",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.3",
        "sectionTitle": "Clinical efficacy and safety"
      },
      {
        "id": "nci_3_1",
        "name": "RATIONALE FOR PERFORMING THE TRIAL",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "RATIONALE FOR PERFORMING THE TRIAL"
      },
      {
        "id": "nci_3_2",
        "name": "TRIAL OBJECTIVES",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "TRIAL OBJECTIVES"
      },
      {
        "id": "nci_3_3",
        "name": "BENEFIT-RISK ASSESSMENT",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3",
        "sectionTitle": "BENEFIT-RISK ASSESSMENT"
      },
      {
        "id": "nci_4_1",
        "name": "OVERALL TRIAL DESIGN AND PLAN",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "OVERALL TRIAL DESIGN AND PLAN"
      },
      {
        "id": "nci_4_2",
        "name": "Administrative structure of the trial",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Administrative structure of the trial"
      },
      {
        "id": "nci_4_3",
        "name": "Clinical Event Committee",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1.1",
        "sectionTitle": "Clinical Event Committee"
      },
      {
        "id": "nci_4_4",
        "name": "Hepatic external adjudication",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1.2",
        "sectionTitle": "Hepatic external adjudication"
      },
      {
        "id": "nci_4_5",
        "name": "Adjudication of ketoacidosis",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1.1.3",
        "sectionTitle": "Adjudication of ketoacidosis"
      },
      {
        "id": "nci_4_6",
        "name": "DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUP(S)",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUP(S)"
      },
      {
        "id": "nci_4_7",
        "name": "SELECTION OF TRIAL POPULATION",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3",
        "sectionTitle": "SELECTION OF TRIAL POPULATION"
      },
      {
        "id": "nci_4_8",
        "name": "Main diagnosis for trial entry",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.1",
        "sectionTitle": "Main diagnosis for trial entry"
      },
      {
        "id": "nci_4_9",
        "name": "Inclusion criteria",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.2",
        "sectionTitle": "Inclusion criteria"
      },
      {
        "id": "nci_4_10",
        "name": "Exclusion criteria",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.3",
        "sectionTitle": "Exclusion criteria"
      },
      {
        "id": "nci_4_11",
        "name": "Removal of patients from therapy or assessments",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.4",
        "sectionTitle": "Removal of patients from therapy or assessments"
      },
      {
        "id": "nci_4_12",
        "name": "Removal of individual patients",
        "text": "",
        "order": 11,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.4.1",
        "sectionTitle": "Removal of individual patients"
      },
      {
        "id": "nci_4_13",
        "name": "Discontinuation of the trial by the Sponsor",
        "text": "",
        "order": 12,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3.4.2",
        "sectionTitle": "Discontinuation of the trial by the Sponsor"
      },
      {
        "id": "nci_5_1",
        "name": "INVESTIGATIONAL TREATMENTS",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "INVESTIGATIONAL TREATMENTS"
      },
      {
        "id": "nci_5_2",
        "name": "Identity of the investigational Medicinal product and comparator",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.1",
        "sectionTitle": "Identity of the investigational Medicinal product and comparator"
      },
      {
        "id": "nci_5_3",
        "name": "Selection of doses in the trial",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.2",
        "sectionTitle": "Selection of doses in the trial"
      },
      {
        "id": "nci_5_4",
        "name": "Method of assigning patients to treatment groups",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.3",
        "sectionTitle": "Method of assigning patients to treatment groups"
      },
      {
        "id": "nci_5_5",
        "name": "Drug assignment and administration of doses for each patient",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.4",
        "sectionTitle": "Drug assignment and administration of doses for each patient"
      },
      {
        "id": "nci_5_6",
        "name": "Blinding and procedures for unblinding",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.5",
        "sectionTitle": "Blinding and procedures for unblinding"
      },
      {
        "id": "nci_5_7",
        "name": "Blinding",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.5.1",
        "sectionTitle": "Blinding"
      },
      {
        "id": "nci_5_8",
        "name": "Unblinding and breaking the code",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.5.2",
        "sectionTitle": "Unblinding and breaking the code"
      },
      {
        "id": "nci_5_9",
        "name": "Packaging, labelling and re-supply",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.6",
        "sectionTitle": "Packaging, labelling and re-supply"
      },
      {
        "id": "nci_5_10",
        "name": "Storage conditions",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.7",
        "sectionTitle": "Storage conditions"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "BI",
        "expandedText": "Boehringer Ingelheim",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "HF",
        "expandedText": "Heart Failure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "HFrEF",
        "expandedText": "Heart Failure with reduced Ejection Fraction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "LVEF",
        "expandedText": "Left Ventricular Ejection Fraction",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 5,
      "itemCount": 31,
      "abbreviationCount": 4
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "c09098452-04",
      "versionDate": "20 Nov 2019",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "BI",
          "expansion": "Boehringer Ingelheim"
        },
        {
          "abbreviation": "HF",
          "expansion": "Heart Failure"
        },
        {
          "abbreviation": "HFrEF",
          "expansion": "Heart Failure with reduced Ejection Fraction"
        },
        {
          "abbreviation": "LVEF",
          "expansion": "Left Ventricular Ejection Fraction"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).",
        "version": "c09098452-04",
        "versionDate": "20 Nov 2019"
      },
      "sections": [
        {
          "number": "N/A",
          "title": "CLINICAL TRIAL PROTOCOL SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "MEDICAL BACKGROUND"
            },
            {
              "number": "1.2",
              "title": "DRUG PROFILE"
            },
            {
              "number": "1.2.1",
              "title": "Non-clinical assessment of safety"
            },
            {
              "number": "1.2.2",
              "title": "Clinical pharmacokinetics"
            },
            {
              "number": "1.2.3",
              "title": "Clinical efficacy and safety"
            }
          ]
        },
        {
          "number": "2",
          "title": "RATIONALE, OBJECTIVES, AND BENEFIT-RISK ASSESSMENT",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "RATIONALE FOR PERFORMING THE TRIAL"
            },
            {
              "number": "2.2",
              "title": "TRIAL OBJECTIVES"
            },
            {
              "number": "2.3",
              "title": "BENEFIT-RISK ASSESSMENT"
            }
          ]
        },
        {
          "number": "3",
          "title": "DESCRIPTION OF DESIGN AND TRIAL POPULATION",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "OVERALL TRIAL DESIGN AND PLAN"
            },
            {
              "number": "3.1.1",
              "title": "Administrative structure of the trial"
            },
            {
              "number": "3.1.1.1",
              "title": "Clinical Event Committee"
            },
            {
              "number": "3.1.1.2",
              "title": "Hepatic external adjudication"
            },
            {
              "number": "3.1.1.3",
              "title": "Adjudication of ketoacidosis"
            },
            {
              "number": "3.2",
              "title": "DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF CONTROL GROUP(S)"
            },
            {
              "number": "3.3",
              "title": "SELECTION OF TRIAL POPULATION"
            },
            {
              "number": "3.3.1",
              "title": "Main diagnosis for trial entry"
            },
            {
              "number": "3.3.2",
              "title": "Inclusion criteria"
            },
            {
              "number": "3.3.3",
              "title": "Exclusion criteria"
            },
            {
              "number": "3.3.4",
              "title": "Removal of patients from therapy or assessments"
            },
            {
              "number": "3.3.4.1",
              "title": "Removal of individual patients"
            },
            {
              "number": "3.3.4.2",
              "title": "Discontinuation of the trial by the Sponsor"
            }
          ]
        },
        {
          "number": "4",
          "title": "TREATMENTS",
          "type": "Treatment",
          "subsections": [
            {
              "number": "4.1",
              "title": "INVESTIGATIONAL TREATMENTS"
            },
            {
              "number": "4.1.1",
              "title": "Identity of the investigational Medicinal product and comparator"
            },
            {
              "number": "4.1.2",
              "title": "Selection of doses in the trial"
            },
            {
              "number": "4.1.3",
              "title": "Method of assigning patients to treatment groups"
            },
            {
              "number": "4.1.4",
              "title": "Drug assignment and administration of doses for each patient"
            },
            {
              "number": "4.1.5",
              "title": "Blinding and procedures for unblinding"
            },
            {
              "number": "4.1.5.1",
              "title": "Blinding"
            },
            {
              "number": "4.1.5.2",
              "title": "Unblinding and breaking the code"
            },
            {
              "number": "4.1.6",
              "title": "Packaging, labelling and re-supply"
            },
            {
              "number": "4.1.7",
              "title": "Storage conditions"
            }
          ]
        }
      ]
    }
  }
}